Aaron S. Meadows

Feasibility and Safety of Systemic rAAV9-h<i>NAGLU</i> Delivery for Treating Mucopolysaccharidosis IIIB: Toxicology, Biodistribution, and Immunological Assessments in Primates

Darren Murrey, Bartholomew J. Naughton, F. Jason Duncan et al. · Human Gene Therapy Clinical Development · 2014 · 87 citations · Full text

Mucopolysaccharidosis Iiib, Immunotoxicology, Immunodeficiencies +18

Blood Genome-Wide Transcriptional Profiles Reflect Broad Molecular Impairments and Strong Blood-Brain Links in Alzheimer's Disease

Bartholomew J. Naughton, F. Jason Duncan, Darren Murrey et al. · Journal of Alzheimer s Disease · 2014 · 58 citations · Full text

Neurogenomics, Genetics, Neurochemical Biomarkers +23

Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery

Haiyan Fu, Marcela P. Cataldi, Tierra Ware et al. · Molecular Therapy — Methods & Clinical Development · 2016 · 58 citations · Full text

Immunology, Functional Correction, Mps Iiia +18

Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy

Haiyan Fu, Aaron S. Meadows, Ricardo Pineda et al. · Human Gene Therapy Clinical Development · 2017 · 42 citations · Full text

Immunodeficiencies, Immunology, Viral Pathogenesis +16

Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting

Victoria M. Velazquez, Aaron S. Meadows, Ricardo Pineda et al. · Molecular Therapy — Methods & Clinical Development · 2017 · 38 citations · Full text